TABLE 2.
Characteristics of serum panels
| Panel | Serological status | No. of samples | GMT (range) or resulta
|
Source or characteristic | |||
|---|---|---|---|---|---|---|---|
| VCA IgG | VCA IgM | EA IgG | EBNA IgG | ||||
| A | Seronegative | 78 | − | − | − | − | Mainly children |
| B | Past infection | 26 | 173.3 (80–640) | − | ND | 68.2 (20–320) | |
| C | Reactivationb | 14 | 2,195.0 (1,280–5,120) | − | 205.9 (<5–640) | 67.3 (<5–160) | Immunosuppressed patients or patients with an EBV-associated tumor |
| D | Primary infection | 37 | 195.0 (<5–1,280) | + | ND | 6.3 (<5–10) | Heterophile antibodies (19 samples) |
| E | IgM cross-reactivityc | 21 | 271.8 (<5–5,120) | ND | ND | 28.3 (<5–80) | |
| F | Routine diagnosis | 47 | 324.9 (<5–5,120) | ND | ND | 36.7 (<5–320) | |
| G | Past infection without EBNA | 34 | 277.4 (80–1,280) | ND | ND | − | Healthy adults |
a
GMT, geometric mean titer; ND, not done; +, positive result; −, negative result. For VCA IgM antibodies, a single dilution was performed; a titer for the positive value was not quantifiable.
b
Serial samples (n = 34) from five organ transplant recipients were added to this panel.
c
Two hepatitis A virus samples, one hepatitis B virus sample, six cytomegalovirus samples, six herpes simplex virus samples, two varicella-zoster virus samples, two mumps virus samples, and two measles virus samples.